Provided by Tiger Trade Technology Pte. Ltd.

Eton Pharmaceuticals, Inc.

56.80
-1.0800-1.87%
Volume:263.32K
Turnover:15.09M
Market Cap:1.62B
PE:145.64
High:59.95
Open:58.99
Low:56.45
Close:57.88
52wk High:66.37
52wk Low:14.27
Shares:28.58M
Float Shares:22.30M
Volume Ratio:0.64
T/O Rate:1.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.3900
EPS(LYR):-0.1710
ROE:35.97%
ROA:11.86%
PB:34.85
PE(LYR):-332.18

Loading ...

Aug 28, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 24, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 19, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Aug 14, 2026

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 14, 2026

Major Issues Report

Form 8-K - Current report
Aug 05, 2026

Major Issues Report

Form 8-K - Current report
Aug 04, 2026

Major Issues Report

Form 8-K - Current report
Jul 29, 2026

Major Issues Report

Form 8-K - Current report
Jul 29, 2026

Beneficial Ownership Change

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Jun 26, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 25, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 23, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 17, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 09, 2026

Major Issues Report

Form 8-K - Current report
Jun 02, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 28, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 22, 2026

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 19, 2026

Major Issues Report

Form 8-K - Current report
May 14, 2026

Major Issues Report

Form 8-K - Current report
May 14, 2026

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]